07/2021
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
Gastroenterology
Read More
06/2021
Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640
EASL International Liver Congress
Read More
04/2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
EClinicalMedicine
Read More
11/2020
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
AASLD
Read More
09/2020
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
European Society for Medical Oncology (ESMO) Congress
Read More
08/2020
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
EASL International Liver Congress
Read More
08/2020
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
Read More
07/2020
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
Hepatology 2020
Read More
06/2019
Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab
ASCO
Read More